Search
Jiangsu InnoNova Biotechnology Co., Ltd. has recently declared the successful closure of back-to-back Angel Round and Pre-A Round funding, amassing a total exceeding 100 million yuan within a single year. This funding round was spearheaded by Addor Capital and Tianhui Capital, and saw contributions from a range of investors, including Luxin Venture Capital. The newly acquired capital will be predominantly allocated towards refining the LNP delivery technology platform, boosting GMP manufacturing capabilities, and fueling international business expansion. These strategic moves aim to solidify the company's competitive edge in the global mRNA and delivery system sectors, while fostering innovation and industrialization in the realm of nucleic acid drugs worldwide.
-
C114 Communication Network -
Communication Home
